Tevogen (TVGN) Common Equity (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Common Equity came in at -$9.8 million in Q1 2026, down 27.49% YoY from -$13.6 million in Q1 2025, and down 19.52% on a QoQ basis from -$8.2 million in Q4 2025.
Tevogen (TVGN) Common Equity (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Common Equity data on file, last reported at -$9.8 million in Q1 2026.
- Quarterly Common Equity fell 27.49% year-over-year to -$9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (down 27.49% YoY) and the FY2025 annual result came in at -$8.2 million, down 23.39% from the prior year.
- Common Equity declined to -$9.8 million in Q1 2026, from -$8.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$5.8 million in Q1 2024 to a low of -$94.4 million in Q4 2023.
- A 5-year average of -$28.4 million and a median of -$9.8 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity slumped 519.45% — and 2024, when it soared 93.18%.
- Tracing TVGN's Common Equity over 5 years: stood at -$34.0 million in 2022, then slumped by 178.13% to -$94.4 million in 2023, then soared by 92.93% to -$6.7 million in 2024, then decreased by 23.39% to -$8.2 million in 2025, then declined by 19.52% to -$9.8 million in 2026.
- The last three Common Equity figures came in at -$9.8 million (Q1 2026), -$8.2 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 9.79 Bn |
| 10 | Tevogen | 26.21 Mn | 26.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.84 Mn |
| Dec 31, 2025 | -8.23 Mn |
| Sep 30, 2025 | -7.82 Mn |
| Jun 30, 2025 | -9.48 Mn |
| Mar 31, 2025 | -7.72 Mn |
| Dec 31, 2024 | -6.67 Mn |
| Sep 30, 2024 | -6.19 Mn |
| Jun 30, 2024 | -7.66 Mn |
| Mar 31, 2024 | -5.80 Mn |
| Dec 31, 2023 | -94.43 Mn |
| Sep 30, 2023 | -90.80 Mn |
| Jun 30, 2023 | -86.89 Mn |
| Mar 31, 2023 | -64.71 Mn |
| Dec 31, 2022 | -33.95 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Jun 30, 2022 | -14.05 Mn |
| Mar 31, 2022 | -14.25 Mn |
| Dec 31, 2021 | -14.23 Mn |